Gemphire Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.09.24	NeuroBo Pharma Announces Positive Results From Phase 1 Trial Of DA-1726 In Obesity Treatment (RTTNews)
14.08.24	NeuroBo Pharmaceuticals, Inc. Q2 Loss Increases, Misses Estimates (RTTNews)
06.08.24	NeuroBo Pharma In Agreement With Dong-A ST And ImmunoForge To Develop DA-1726 To Treat Obesity (RTTNews)
30.07.24	NeuroBo Enters License Agreement With MThera For NB-01 - Quick Facts (RTTNews)
24.06.24	NeuroBo Announces Up To $70 Mln Of Concurrent Private Placement And Registered Offering Of Shares (RTTNews)
22.05.24	NeuroBo Pharma Reveals Positive Pre-clinical Data For DA -1241 In Combination In Liver Fibrosis (RTTNews)
13.03.24	NeuroBo Pharma Gets Approval To Proceed With Phase 2a Trial For DA-1241 To Treat MASH; Stock Up 8% (RTTNews)
04.03.24	NeuroBo Pharmaceuticals Confirms Marshall Woodworth As New CFO (RTTNews)
29.02.24	NeuroBo Receives First Site IRB Approval For DA-1726 Obesity Trial; Stock Gains (RTTNews)
01.02.24	NeuroBo Rises 48% On Receiving FDA Approval For IND Application For DA-1726 (RTTNews)
01.02.24	NeuroBo Pharma'a IND Application For DA-1726 Gets FDA Clearance (RTTNews)
18.01.24	NeuroBo Announces Positive Pre-Clinical Safety Data Of DA-1241 In Combination With Sitagliptin (RTTNews)
28.12.23	NeuroBo Submits IND Application For Phase 1 Clinical Trial Of DA-1726; Stock Up In Pre-market (RTTNews)
14.08.23	NeuroBo Appoints Hyung Heon Kim As CEO (RTTNews)
18.01.23	NeuroBo Pharma Names Joseph Hooker Interim CEO & President - Quick Facts (RTTNews)
09.12.22	Pre-market Movers: BXRX, CNCE, GROM, NRBO, BHIL… (RTTNews)
08.11.22	Pre-market Movers: NRBO, HIMS, OCUP, TRIP, TTWO… (RTTNews)
21.09.22	Pre-market Movers: IE, SOBR, DNB, LITM, AMPX… (RTTNews)
15.09.22	NeuroBo Agrees With Dong-A To Develop DA-1241 & DA-1726 For NASH/Type 2 Diabetes/Obesity (RTTNews)
14.09.22	Pre-market Movers: DWIN, SES, KSPN, NRBO, EPM… (RTTNews)
13.09.22	Pre-market Movers: AKRO, ETNB, CMRA, RENT, CRDF… (RTTNews)
12.09.22	NeuroBo Pharma Announces 1-for-30 Reverse Split Of Common Stock - Quick Facts (RTTNews)
25.01.22	Pre-market Movers: APM, BSFC, INPX, UPC, KAVL… (RTTNews)
24.01.22	Pre-market Movers: BTBD, RETO, KSS, BON, PT… (RTTNews)
13.10.21	NeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without Modification (RTTNews)
28.09.21	Pre-market Movers: PLAG, ZIVO, IPW, FEIM, FAMI… (RTTNews)
16.08.21	NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results (PR Newswire)
12.07.21	NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors (PR Newswire)
06.01.21	Stock Alert: NeuroBo Pharma Up 25% (RTTNews)
06.01.21	NeuroBo Pharma Acquires ANA Therapeutics - Quick Facts (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	125.85	2.57 %	K V
Sika	232.30	1.84 %	K V
Swiss Re	132.20	1.58 %	K V
Logitech Intl	72.56	1.48 %	K V
ABB	51.02	1.47 %	K V
Nestle	76.60	0.16 %	K V
Sonova Hldg	300.80	0.00 %	K V
Novartis	93.14	-0.14 %	K V
Swisscom	507.00	-0.29 %	K V
Alcon	78.06	-0.41 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Gemphire Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten